Remus Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
REMUS
Pharmaceuticals
Track Remus Pharmaceuticals share price live with TickJournal's free stock screener.
Analyze Remus Pharmaceuticals share price history trends and compare 52-week high low
levels.
Calculate REMUS stock fair value using fundamental analysis and view live share price charts.
Determine Remus Pharmaceuticals share intrinsic value and compare it with current REMUS share price.
Record your Remus Pharmaceuticals trades in TickJournal's free trading journal and track your portfolio performance.
Remus Pharmaceuticals Market Cap
₹770.20 Cr.
EPS (TTM)
₹65.21
Dividend Yield
0.11%
Debt to Equity
0.09
Remus Pharmaceuticals 52 Week Low
-
Operating Margin
-
Profit Margin
-
EBITDA
-
Net Income
-
Total Assets
₹433.00
Total Equity
₹283.00
Remus Pharmaceuticals Share Price History - Stock Screener Chart
Screen REMUS historical share price movements with interactive charts. Analyze price trends and patterns.
Remus Pharmaceuticals Company Profile - Fundamental Screener
Screen Remus Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for REMUS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0O5T01011
Remus Pharmaceuticals Balance Sheet Screener
Screen REMUS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 |
|---|---|---|
| Assets | ||
| Total Assets | 433 | 333 |
| Current Assets | 221 | 212 |
| Fixed Assets | 16 | 14 |
| Liabilities | ||
| Total Liabilities | 433 | 333 |
| Current Liabilities | 29 | 17 |
| Non-Current Liabilities | 0 | 0 |
| Shareholders' Equity | ||
| Total Equity | 283 | 175 |
| Share Capital | 6 | 2 |
| Reserves & Surplus | 250 | 156 |
Remus Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Remus Pharmaceuticals income statement and profit fundamentals.
Analyze REMUS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Remus Pharmaceuticals share price evaluation.
| Item | None-None | 2025-March | 2024-March |
|---|---|---|---|
| Revenue | 0 | 625 | 216 |
| Expenses | 0 | 575 | 184 |
| EBITDA | 0 | 51 | 32 |
| Operating Profit % | 0.00% | 7.00% | 14.00% |
| Depreciation | 0 | 2 | 1 |
| Interest | 0 | 2 | 1 |
| Profit Before Tax | 0 | 47 | 30 |
| Tax | 0 | 9 | 6 |
| Net Profit | 0 | 38 | 24 |
| EPS | 0.00 | 65.21 | 42.97 |
Remus Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen REMUS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March |
|---|---|---|
| Operating Activities | 7 | 1 |
| Investing Activities | -11 | -25 |
| Financing Activities | 6 | 28 |
| Net Cash Flow | 3 | 4 |
Remus Pharmaceuticals Shareholding Pattern Screener
See Remus Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Remus Pharmaceuticals promoter holding and ownership changes for REMUS on TickJournal.
| Item | 2025-Sept | 2025-Jul | 2025-Mar | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Sept | 2023-May |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 70.91% | 70.85% | 70.85% | 70.84% | 70.66% | 70.60% | 69.61% | 68.37% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.92% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 18.78% | 18.90% | 19.18% | 20.49% | 20.90% | 20.54% | 21.15% | 16.69% |
| Other Holding | 10.32% | 10.25% | 9.97% | 8.67% | 8.44% | 8.85% | 9.24% | 14.02% |
| Shareholder Count | 2,032 | 2,017 | 398 | 1,753 | 1,577 | 1,124 | 856 | 1,743 |
Remus Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Remus Pharmaceuticals dividend history with payout and yield data.
View Remus Pharmaceuticals dividend details including ex-dates and amounts for REMUS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.50 | 0.22% |
| 2024-March | ₹6.00 | 0.27% |
| 2023-March | ₹2.00 | 0.03% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Remus Pharmaceuticals Stock Index Membership
See which indices include Remus Pharmaceuticals stock.
Check REMUS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Remus Pharmaceuticals Market Events Screener - Corporate Actions
Get Remus Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Remus Pharmaceuticals stock events that may affect REMUS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -8.04% | ||
| Dividend | ₹ 2.00 /share | - | ||
| Dividend | ₹ 0.50 /share | -63.25% | ||
| 2025-11-14 | 2025-11-14 | Dividend | ₹ 0.50 /share | -5.20% |
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | 11.96% |
| 2025-07-04 | 2025-07-04 | Bonus | 1:1 | -3.13% |
| 2025-05-17 | 2025-05-17 | Quarterly Result Announcement | NA | 20.47% |
| 2024-11-19 | 2024-11-20 | Dividend | ₹ 1.00 /share | -7.10% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | -0.23% |
| 2024-06-06 | 2024-06-06 | Bonus | 3:1 | 0.38% |
| 2024-05-21 | 2024-05-21 | Extraordinary General Meeting | NA | 25.37% |
| 2024-05-02 | 2024-05-02 | Dividend | ₹ 4.00 /share | 16.23% |
| 2024-03-13 | 2024-03-13 | Extraordinary General Meeting | NA | -21.44% |
| 2023-10-27 | 2023-10-28 | Dividend | ₹ 2.00 /share | 1.92% |
Remus Pharmaceuticals Competitors Screener - Peer Comparison
Screen REMUS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 408,007 | 37.20 | 54,729 | 9.71% | 10,980 | 53.25 |
| Divis Laboratories | 163,250 | 66.07 | 9,712 | 18.67% | 2,191 | 48.15 |
| Torrent Pharmaceuticals | 144,229 | 64.43 | 11,539 | 6.99% | 1,911 | 70.35 |
| Cipla | 109,566 | 23.71 | 28,410 | 7.12% | 5,291 | 45.95 |
| Dr Reddys Laboratories | 105,948 | 19.16 | 33,741 | 16.73% | 5,725 | 58.53 |
| Lupin | 101,478 | 21.52 | 22,910 | 13.74% | 3,306 | 60.82 |
| Zydus Life Science | 91,613 | 18.12 | 23,511 | 18.55% | 4,615 | 52.96 |
| Mankind Pharma | 86,000 | 47.17 | 12,744 | 20.90% | 2,007 | 45.43 |
| Aurobindo Pharma | 68,802 | 19.14 | 32,346 | 9.43% | 3,484 | 51.95 |
| Alkem Laboratories | 65,528 | 26.80 | 13,458 | 3.70% | 2,216 | 40.44 |
Remus Pharmaceuticals Company Announcements - News Screener
Screen REMUS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.